Using AI to identify lymph node metastasis in gastric cancer
Hebei Medical University
Hebei Medical University · NCT06534814
This study is testing a new AI tool to see if it can better identify lymph node spread in people with gastric cancer compared to regular diagnostic methods.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hebei Medical University (other) |
| Locations | 1 site (Shijiazhuang, Hebei) |
| Trial ID | NCT06534814 on ClinicalTrials.gov |
What this trial studies
This study focuses on developing an artificial intelligence-driven model to accurately identify lymph node metastasis in patients with gastric cancer. A multidisciplinary team, including oncologists, radiologists, and data scientists, will collaborate to create this model. Participants will undergo standard diagnostic procedures, and the AI model will analyze imaging and pathological data to predict lymph node involvement. The study aims to validate the AI model's accuracy by comparing its predictions with traditional diagnostic methods.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a confirmed diagnosis of gastric cancer and suspected or confirmed lymph node involvement.
Not a fit: Patients who are pregnant, have severe comorbid conditions, or have previously used AI-driven diagnostic interventions for gastric cancer lymph node metastasis may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate staging and treatment planning for gastric cancer patients.
How similar studies have performed: While the use of AI in medical diagnostics is growing, this specific application for gastric cancer lymph node metastasis is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Diagnosis of Gastric Cancer: Confirmed diagnosis of gastric cancer, either newly diagnosed or recurrent. 2. Lymph Node Involvement: Suspected or confirmed involvement of lymph nodes, as indicated by imaging studies or pathology reports. 3. Age: Patients aged 18 years or older. 4. Performance Status: An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, indicating a functional status that allows participation in the study. 5. Informed Consent: Ability to provide written informed consent to participate in the study. Exclusion Criteria: 1. Pregnancy or Lactation: Pregnant or lactating women, due to potential risks to the fetus or infant. 2. Severe Comorbid Conditions: Presence of severe comorbid medical conditions that could interfere with the study or pose additional risks. 3. Previous AI-Driven Diagnostic Intervention: Prior use of any AI-driven diagnostic models specifically for gastric cancer lymph node metastasis. 4. Inability to Comply: Inability or unwillingness to comply with study procedures, including follow-up visits and data collection. 5. Mental or Cognitive Impairment: Conditions that impair the ability to provide informed consent or participate effectively in the study.
Where this trial is running
Shijiazhuang, Hebei
- Department of General Surgery — Shijiazhuang, Hebei, China (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: The Primary Focus of This Study is on Gastric Cancer